[FONT="]NanoLogix is pleased to announce the filing of a patent application for use in the rapid testing for the Covid-19 virus. The application was filed under a new program instituted May 14th by the US Patent and Trademark Office. Now that Patent-Pending status has been obtained, we can reveal aspects of the technology that we were unable to mention in a prior update.[/FONT][FONT="] [/FONT][FONT="]This Rapid Viral Assay is a modified ELISA technology that is not the same as our N-Assay modified ELISA.[/FONT][FONT="]While the initial focus for development was for the COVID-19 virus, it became obvious that the technology[/FONT][FONT="]is not limited to one virus, but can be configured for many different viruses, such as HIV, HPV, Hepatitis, MERS, SARS-1 and others. As per the patent filing, the description is "Without Limitation".[/FONT][FONT="] [/FONT][FONT="] [/FONT][FONT="]An additional aspect of the test is that for the Home-Test configuration, we anticipate the potential of 30-minute results using a nasopharyngeal swab sample or saliva.[/FONT][FONT="] [/FONT][FONT="]Jonathan Faro, MD, PhD., our Chief Medical Officer stated "We are extremely excited over this technology development, as it is a novel approach in diagnostics that provides a solution to the inherent problems with false positives and false negatives present in those tests currently being used in the war against COVID-19." [/FONT][FONT="] [/FONT][FONT="] [/FONT][FONT="]The US Patent Office program under which the filing was done can be accessed through the following link:[/FONT][FONT="] [/FONT][FONT="]https://www.federalregister.gov/documents/2020/05/14/2020-10372/covid-19-prioritized-examination-pilot-program[/FONT]